i2o Therapeutics is developing proprietary products for cardio-metabolic diseases and adjacent indications.
i2o’s medicines combined with differentiated delivery platforms hold the promise of raising the current standard of care
Product
Preclinical
Clinical
Filed (with US FDA)
FDA Approval
Indication(s)
ITCA 650 (GLP-1 RA, Exenatide, Twice yearly)
T2D
i2o-105s (LA GLP-1 RA)
T2D, Obesity, NASH
i2o-107 (LA Amylin)
T2D, Obesity, NASH
i2o-110 (Dual agonist combination)
T2D, Obesity, NASH
i2o-120 (LA PYY)
T2D, Obesity, NASH
i2o-130 (LA Glucagon)
T2D, Obesity, NASH